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Summary
Defective apoptosis not only promotes tumorigenesis, but also can confound chemotherapeutic response. Here we de-
monstrate that the proapoptotic BH3-only protein BIM is a tumor suppressor in epithelial solid tumors and also is a
determinant in paclitaxel sensitivity in vivo. Furthermore, the H-ras/mitogen-activated protein kinase (MAPK) pathway
conferred resistance to paclitaxel that was dependent on functional inactivation of BIM. Whereas paclitaxel induced BIM
accumulation and BIM-dependent apoptosis in vitro and in tumors in vivo, the H-ras/MAPK pathway suppressed this BIM
induction by phosphorylating BIM and targeting BIM for degradation in proteasomes. The proteasome inhibitor Velcade
(P-341, Bortezomib) restored BIM induction, abrogated H-ras-dependent paclitaxel resistance, and promoted BIM-depen-
dent tumor regression, suggesting the potential benefits of combinatorial chemotherapy of Velcade and paclitaxel.S I G N I F I C A N C E
Tumorigenesis results in the acquisition of mutations that promote tumor growth and chemoresistance, and relating tumor genotype
to prognostic indications and to effective treatment regimens is essential for successful therapeutic outcome. Determining the
mechanism of apoptosis induction by the chemotherapeutic drug paclitaxel revealed that BIM suppressed tumorigenesis and was
required for paclitaxel responsiveness. The targeting of BIM for degradation in proteasomes by the H-ras/MAPK pathway was the
molecular basis for paclitaxel resistance in tumors with activating mutations in RAS, and paclitaxel responsiveness was restored by
joint administration of the proteasome inhibitor Velcade. Thus, rational combinatorial chemotherapy using proteasome inhibitors to
enhance chemosensitivity to paclitaxel in tumors where the H-ras/MAPK pathway is activated may be therapeutically beneficial.Introduction
Programmed cell death or apoptosis occurs in response to devel-
opmental cues and disease states, and serves to sculpt tissues,
eradicate abnormal or infected cells, and maintain homeostasis.
Acquired resistance toward apoptosis is considered to be a uni-
versal feature of cancer (Cory et al., 2003; Hanahan and Wein-
berg, 2000). Defects in apoptosis not only provide cancer cells
with an intrinsic survival advantage, but may also confer inher-
ent resistance to chemotherapeutic drugs (Johnstone et al.,
2002). BCL-2 family proteins are central players in the regula-
tion of apoptosis, and modulate death signaling through the
intrinsic or mitochondrial pathway (Cory and Adams, 2002).
Whereas BCL-2 and several close relatives promote cell sur-
vival, other family members that share several domains with
BCL-2, such as BAX and BAK, instead favor apoptosis. Mem-
bers of the more distantly related BH3-only subfamily (BIM,
PUMA, NOXA, BID, BAD, and BIK, for example) have the criti-
cal role of initiating the apoptotic program. They act by antago-
nizing the function of antiapoptotic BCL-2 and its homologs,CANCER CELL : MARCH 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INand perhaps also by directly activating the function of BAX and
BAK (Adams, 2003b). Either BAX or BAK is required for apo-
ptosis, which is associated with their oligomerization in the
mitochondrial outer membrane and its permeablization to pro-
apoptotic mitochondrial proteins such as cytochrome c and
SMAC/Diablo. Loss of both BAX and BAK therefore results in
profound resistance to many apoptotic stimuli, including death
receptor signaling and genotoxic agents (Degenhardt et al.,
2002a; Wei et al., 2001; Zong et al., 2001).
The strong impact of the BCL-2 family on tumor develop-
ment is well illustrated by findings with baby mouse kidney
epithelial (BMK) cells transformed by E1A and dominant nega-
tive p53 (p53DD). Transformed BMK cells from mice deficient
for both BAX and BAK, or that overexpress BCL-2, readily form
tumors in nude mice, whereas those retaining functional BAX
and/or BAK do not (Degenhardt et al., 2002a; Nelson et al.,
2004). In epithelial cells, ischemic conditions in the tumor mi-
croenvironment cause induction of the BH3-only protein PUMA,
and BAX- and BAK-mediated apoptosis that suppresses tu-
morigenesis independent of the RB and p53 pathways (NelsonC. DOI 10.1016/j.ccr.2005.02.008 227
A R T I C L Eet al., 2004). Blockade of this p53-independent apoptotic path-
way by either loss-of-function of BAX and BAK or gain-of-func-
tion of BCL-2 in vivo does not merely extend viability, but also
allows survival of genetically unstable cells which may further
promote tumor development (Nelson et al., 2004). However,
how the RB, p53, and BCL-2 pathways impact chemothera-
peutic response and functionally interact with other known
pathways, such as those of receptor tyrosine kinases, is still
not clear.
The frequent activation of RAS signaling pathways during tu-
morigenesis is also likely to reflect in part their ability to inhibit
apoptosis (Downward, 2003). Downstream of RAS, AKT/PKB
signaling has been shown to desensitize cells to apoptosis by
phosphorylating various targets, whereas the mechanisms by
which the RAF/MAPK pathway blocks apoptosis are less well
defined. In the MAPK pathway, a survival signal is transduced
from RAS through serine/threonine kinase RAF, which in turn
phosphorylates and activates MAPK kinases MEK1/2 and
thereby the p42/44 MAPK (ERK1/2) (Downward, 2003). The
MEK/ERK cascade can inhibit apoptosis by upregulating the
antiapoptotic proteins BCL-2, BCL-XL, and MCL-1 (Jost et al.,
2001; Leu et al., 2000; Liu et al., 1999). It may also promote
survival both by phosphorylating BCL-2 and blocking its deg-
radation in proteasomes (Dimmeler et al., 1999) and by phos-
phorylating BIM and accelerating its proteasomal degradation
(Akiyama et al., 2003; Ley et al., 2003; Luciano et al., 2003).
In this study, we have investigated the role of BIM and its
regulation by the RAS/RAF/MAPK pathway in control of apo-
ptosis during both tumorigenesis and chemotherapeutic re-
sponse. There are two major BIM isoforms: the longer BIM-EL
predominating over BIM-L, and a shorter form (BIM-S) which
is sometimes detectable (O’Connor et al., 1998). A central role
for BIM-mediated apoptosis in maintenance of hematopoietic
homeostasis was indicated by the aberrant accumulation of
lymphoid and myeloid cells in BIM-deficient mice (Bouillet et
al., 1999; Bouillet et al., 2002). BIM functions through protein-
protein interactions, and its proapoptotic activity can be inhib-
ited by association with BCL-2, BCL-XL, BCL-w, and MCL-1
(Opferman et al., 2003; Wilson-Annan et al., 2003; Yamaguchi
and Wang, 2002; Zhu et al., 2004). Genetic evidence for the
mutually antagonistic roles of BIM and BCL-2 came with the
demonstration that the apoptosis of kidney cells, melanocytes,
and lymphocytes provoked by BCL-2 deficiency was pre-
cluded by concomitant deficiency for BIM (Bouillet et al., 2001).
Finally, BIM also interacts with microtubule-associated dynein
complex by binding to dynein light chain 1 (DLC1) LC8, which
may relate BIM function to regulation of the cytoskeleton (Pu-
thalakath et al., 1999).
BIM has been reported to be a tumor suppressor for mature
B lymphocytes in Eµ-myc-transgenic mice, and is haploinsuffi-
cient (Egle et al., 2004). However, due to the multiplicity of
BH3-only proteins, and the complexity of their expression and
regulation, it is not possible to predict whether BIM could serve
that role in other cell types, such as the epithelial cells that
produce all the common solid tumors. Interestingly, in vitro
studies (Bouillet et al., 1999; Sunters et al., 2003) have also
implicated BIM in the apoptosis induced by paclitaxel, an anti-
cancer agent that interferes with microtubule dynamics. Pacli-
taxel is a frontline antineoplastic agent that is efficacious in
the treatment of a number of malignancies, including ovarian,
breast, lung, and prostate cancers. Although it is known to sta-228bilize microtubules, causing mitotic arrest and activating the
spindle assembly checkpoint, the signal transduction path-
ways by which paclitaxel induces apoptosis are still poorly
understood (Bhalla, 2003).
We have developed and utilized isogenic transformed epi-
thelial cells with defined combinations of gain- and loss-of-
function mutations to evaluate the impact on both tumor growth
and treatment response. We report here that paclitaxel induces
BIM accumulation that is required for paclitaxel-induced apo-
ptosis both in vitro and in vivo. However, constitutive activation
of the H-ras/MAPK pathway suppresses BIM induction by
phosphorylating BIM and targeting BIM for degradation in pro-
teasomes, thereby blocking response to paclitaxel. Neverthe-
less, in cells with the RAS pathway activated, combined treat-
ment with a proteasome inhibitor and paclitaxel restores BIM
accumulation and apoptosis. Finally, we show that BIM is in-
deed a tumor suppressor in epithelial cells, and that BIM defi-
ciency results in paclitaxel-resistant tumors. This provides a
mechanistic explanation for chemotherapeutic-mediated apo-
ptosis and suggests that combining a proteasome inhibitor
with paclitaxel would provide therapeutic benefit among tu-
mors with H-ras/MAPK pathway activation.
Results
Expression of H-ras confers resistance to paclitaxel
Since mutations that activate a ras gene are among the most
common found in tumors, we sought to determine how consti-
tutive RAS activity alters the apoptotic response during che-
motherapy. Hence, we have investigated how imposed H-ras
expression affects the paclitaxel sensitivity of transformed
BMK epithelial cells with genetically defined defects in apopto-
sis. Transformed BMK cells that express BAX and BAK (W2
cells) (Degenhardt et al., 2002a) were transfected with plasmids
directing constitutive expression of H-ras or BCL-2, or with the
vector. Isogenic BAX- and BAK-deficient transformed BMK
cells (D3 cells) (Degenhardt et al., 2002a) were also transfected
with plasmids directing constitutive expression of H-ras or with
the vector to test if H-ras enhanced the survival in the back-
ground of BAX/BAK deficiency. Three independent clones of
each genotype that stably express H-ras (data not shown) were
treated with paclitaxel and viability was determined. The viabil-
ity of one representative clone of each genotype is shown in
Figure 1A.
Importantly, the vector control cell line derived from W2 cells
(W2.3.1-5) was readily killed by paclitaxel, and this cell death was
blocked by the expression of H-ras (W2.Hras-3). Expression of
antiapoptotic BCL-2 (W2.Bcl2-3) or deficiency of proapoptotic
BAX and BAK (D3.zeo-2) (Nelson et al., 2004) conferred slightly
more resistance to apoptosis than H-ras (W2.Hras-3) (Figure 1A).
Furthermore, the expression of H-ras in BAX/BAK-deficient cells
(D3.Hras-1) did not further enhance survival (Figure 1A), suggest-
ing that H-ras inhibited paclitaxel-mediated apoptosis by block-
ing the BAX/BAK apoptotic pathway.
Paclitaxel induces BIM accumulation
that is blocked by H-ras
As BH3-only proteins are essential triggers of apoptosis up-
stream of BAX and BAK (Adams, 2003b; Cheng et al., 2001),
H-ras might act by affecting the function of BH3-only proteins
that mediate paclitaxel-induced apoptosis. The resistance ofCANCER CELL : MARCH 2005
A R T I C L EFigure 1. H-ras phosphorylates BIM, blocks BIM
induction by paclitaxel, and confers resistance
to paclitaxel
A: Viability of transformed BMK cells in response
to paclitaxel. W2.3.1-5, W2.Bcl2-3, W2.Hras-3,
D3.Hras-1, and D3.zeo-2 were treated with 300
nM paclitaxel for four days. The viable cell
number was counted before (day 0) and each
day after treatment by trypan blue exclusion.
Results are presented as relative survival with er-
ror bars representing standard deviation.
B: Paclitaxel induces BIM accumulation, which
is blocked by H-ras. W2.3.1-5, W2.Hras-3, D3.zeo-2,
and D3.Hras-1 were untreated or treated with
300 nM paclitaxel for four days, and the expres-
sion of BH3-only proteins BIM, BID, tBID, PUMA,
and BMF was analyzed by Western blotting. Ac-
tin is shown as a control for protein loading.
C: H-ras causes BIM-EL and BIM-L phosphoryla-
tion. D3.zeo-2 and D3.Hras-1 whole cell lysates
were incubated with lambda protein phospha-
tase, resolved by SDS-PAGE, and Western blot-
ted for BIM to establish that the slower migrating
forms of BIM are the result of phosphorylation.BIM-deficient lymphocytes in vitro to paclitaxel (Bouillet et al.,
1999) led us to investigate the role of BIM in H-ras-dependent
paclitaxel resistance in epithelial cells. Western blotting re-
vealed that the levels of BIM-L and particularly the more pre-
dominant BIM-EL isoform were upregulated dramatically in
W2.3.1-5 and D3.zeo-2 cells following paclitaxel treatment
(Figure 1B). As D3.zeo-2 cells did not undergo apoptosis in
response to paclitaxel (Figure 1A), BIM induction was not a
consequence of cell death. Notably, BIM induction by pacli-
taxel was largely abrogated by the H-ras expression in both
W2.Hras-3 and D3.Hras-1 cells (Figure 1B). Thus, H-ras regu-
lates both BIM accumulation and apoptosis by paclitaxel. Be-
cause the levels of other BH3-only proteins, namely BID, tBID,
PUMA, and BMF, were unchanged by paclitaxel treatment (Fig-
ure 1B), BIM appears to have a specific role in paclitaxel-
induced cell death. BIM induction is not merely a general re-
sponse to cellular damage, because another cytotoxic drug,
the topoisomerase II inhibitor etoposide, did not induce BIM
accumulation (see Supplemental Figure S1). Interestingly, BID
was only cleaved to tBID in W2.3.1-5 cells that underwent apo-
ptosis in response to paclitaxel, and not in apoptosis-resistant
D3 cells, suggesting that BID cleavage resulted from caspase
activation (Figure 1B).CANCER CELL : MARCH 2005BIM-EL and BIM-L were present as multiple distinctively mi-
grating bands, the slowest of which were preferentially ob-
served in H-ras-expressing cells (Figure 1B), and BIM-EL is a
substrate for phosphorylation by the RAF/MAPK pathways
downstream of H-ras (Marani et al., 2004). In contrast, W2.3.1-5
and D3.zeo-2 cells predominantly displayed the faster migrat-
ing BIM-EL and BIM-L, suggesting that they were unphosphor-
ylated. To confirm that the slower migrating forms of BIM-EL
and BIM-L resulted from phosphorylation by H-ras, lysates of
D3.zeo-2 and D3.Hras-1 cells were incubated with lambda pro-
tein phosphatase. As expected, phosphatase treatment con-
verted both BIM-EL and BIM-L to monomeric forms with en-
hanced mobility (Figure 1C). Thus, H-ras expression caused
BIM phosphorylation and specifically prevented BIM induction
by paclitaxel, suggesting that H-ras may confer resistance to
the drug by modulating BIM levels.
The MAPK pathway regulates BIM and blocks the
apoptotic response to paclitaxel
To define the downstream effector pathway through which
H-ras interferes with paclitaxel-induced apoptosis, W2 cells
were transfected with the vector, or vectors that express con-
stitutively activated forms of RAF (RAF-CAAX) or AKT (Myr-229
A R T I C L EAKT). Three independent cell lines of each genotype were
treated with paclitaxel, and viability was determined. BMK cells
expressing RAF-CAAX were resistant to paclitaxel to a similar
extent as cells expressing H-ras (Figure 2A). In contrast, cells
expressing Myr-AKT were as sensitive to paclitaxel as vector
control cell lines (Figure 2A). These data suggest that H-ras
provides resistance to paclitaxel in BMK cells through RAF/
MAPK pathway.Figure 2. Activation of MAPK pathway blocks BIM induction and confers
paclitaxel resistance
A: Viability of transformed BMK cells expressing constitutively activated RAF
or AKT in response to paclitaxel. Three independent W2-derived stable BMK
cell lines expressing constitutively activated H-ras, RAF, AKT, or vector con-
trols were treated with 300 nM paclitaxel for four days, and viability was
evaluated as described above. Results are presented as relative survival
with error bars representing standard deviation.
B: H-ras phosphorylates BIM and blocks BIM induction through the RAF/
MAPK pathway. The above cell lines were untreated or treated with 300
nM paclitaxel for three days, and cell extracts were subjected to Western
blotting for BIM. Actin is shown as a loading control.230To test if phosphorylation of BIM by H-ras was also a func-
tion of H-ras signaling through RAF/MAPK pathway, the cell
lines were treated with paclitaxel, and BIM protein levels were
measured by Western blotting. As expected, BIM isoforms
were phosphorylated in H-ras- or RAF-CAAX-expressing cells,
neither of which accumulated BIM in response to paclitaxel
(Figure 2B). In contrast, BIM was unphosphorylated and highly
induced in response to paclitaxel in both W2 vector control
cells and W2 cells expressing Myr-AKT (Figure 2B). Hence,
H-ras may suppress paclitaxel-induced apoptosis through
MAPK pathway by phosphorylating BIM and blocking BIM ac-
cumulation. To confirm that the MEK/ERK pathway down-
stream of H-ras is responsible for phosphorylation of BIM by
H-ras, the specific MEK1/2 inhibitor U0126 was used to block
MEK1/2 activity, which as expected prevented BIM phosphory-
lation in H-ras expressing cells (see Supplemental Figure S2).
H-ras provides resistance to paclitaxel
by preventing BIM accumulation
To determine if paclitaxel-induced apoptosis was mediated by
BIM, multiple independent E1A and p53DD transformed BMK
cell lines that were deficient for BIM (bim−/−) or expressed BIM
(bim+/+) were derived from primary BMK cells from kidneys of
bim−/− and bim+/+ mice, littermates from a bim+/− cross. As ex-
pected, BIM was expressed only in the three independent
bim+/+ cell lines, whereas E1A, p53DD, BAX, and BAK were
expressed in all cell lines (Figure 3A). Significantly, all three
BIM-deficient BMK cell lines (BIM−/−A, B, and C) remained
largely viable following three days of paclitaxel treatment,
whereas all three BIM wild-type BMK cell lines (BIM+/+A, B,
and C) were readily killed, indicating that BIM was required for
paclitaxel-induced apoptosis (Figure 3B).
To determine if H-ras and RAF-CAAX blocked paclitaxel-
induced apoptosis by inhibiting BIM accumulation, the BIM-
deficient BMK cell line BIM−/−A was engineered to express
H-ras (BIM−/−A.Hras-A, B, and C) or RAF-CAAX (BIM−/−A.
Raf-A, B, and C) (Figure 3C). Only H-ras expressing BIM−/−A
cells showed overexpression of RAS, and both H-ras- and
RAF-CAAX-expressing BIM−/−A cells displayed phosphory-
lated ERK, a measure of MAPK activation, which was not pre-
sent in vector control BIM−/−A and BIM+/+A cells (Figure 3C).
These cell lines were then tested for paclitaxel sensitivity to
determine if H-ras and RAF-CAAX-mediated apoptosis-resis-
tance was BIM-dependent. Three independent BIM deficient
cell lines expressing H-ras or RAF-CAAX showed paclitaxel re-
sistance similar to the BIM-deficient control cells (Figures 3D
and 3E). Note that BAX/BAK-deficient D3 cells (with or without
H-ras) were more resistant to paclitaxel than W2.Hras-3 cells
(Figure 1A), presumably because of their extreme defect in
apoptosis. Thus, a gain-of-function of H-ras or RAF in the
background of BIM deficiency should have been apparent. The
absence of a gain-of-function of H-ras or RAF in BIM-deficient
cells indicates that they block paclitaxel-induced apoptosis by
inhibiting BIM.
BIM, but not PUMA, suppresses tumorigenesis
Since tumorigenesis and chemoresistance often concur in
apoptotic defective cells, we investigated the impact of BIM
deficiency on tumorigenesis, by comparing tumor develop-
ment with three independent BIM-deficient (BIM−/−A, B, and C)
and BIM wild-type (BIM+/+A, B, and C) transformed BMK cellCANCER CELL : MARCH 2005
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by blocking BIM induction
A: Generation of wild-type and BIM-deficient
BMK cell lines. Cell extracts generated from
three independent BMK cell lines that express
BIM (BIM+/+A, BIM+/+B, and BIM+/+C), and that
are deficient for BIM (BIM−/−A, BIM−/−B, and
BIM−/−C) were subjected to Western blotting
with antibodies specific for BIM, E1A, p53, BAK,
BAX, and actin.
B: BIM deficiency confers resistance to pacli-
taxel. Three independent BMK cell lines that ex-
press BIM or that are deficient for BIM were
treated with 100 nM paclitaxel for three days,
and viability was evaluated as described
above. Results are presented as relative survival
with error bars representing standard deviation.
C: Generation of BIM-deficient BMK cell lines ex-
pressing H-ras or RAF. Cell extracts generated
from a BMK cell line that expresses BIM (BIM+/+A),
a cell line that is deficient for BIM (BIM−/−A),
and three independent cell lines derived from
BIM−/−A that express H-ras, or RAF-CAAX, along
with vector controls, were subjected to Western
blotting with antibodies specific for H-ras and
phosphorylated ERK. The level of total ERK is
shown as a loading control.
D and E: Overexpression of H-ras or RAF-CAAX
did not further enhance paclitaxel resistance
over BIM deficiency. Three independent BMK
cell lines expressing H-ras (D) or RAF-CAAX (E)
derived from BIM−/−A cells were treated with 100
nM paclitaxel for three days, along with BIM+/+A
cells, BIM−/−A cells, and two independent cell
lines with vector control derived from BIM−/−A,
and viability was evaluated by trypan blue ex-
clusion. Results are presented as relative survival
with error bars representing standard deviation.
Note that H-ras or RAF-CAAX had no additional
capacity to inhibit paclitaxel-mediated apo-
ptosis over BIM deficiency.lines. Moreover, to evaluate if BIM is haploinsufficient in epithe-
lial tumorigenesis, as it was recently shown to be in B lympho-
cytes (Egle et al., 2004), three independent BIM heterozygous
transformed BMK cell lines (BIM+/−A, B, and C) were also
tested. Cells from all the lines were injected subcutaneously
into nude mice, and tumor growth was monitored.
As previously reported (Degenhardt et al., 2002a; Nelson et
al., 2004), the BAX/BAK-deficient control (D3) formed large tu-
mors (carcinomas) within 30 days, whereas a transformed cell
line expressing BAX and BAK (W2) formed no measurable tu-
mors (Figure 4A). Significantly, two of the three BIM-deficient
transformed BMK cell lines formed tumors at a rate compara-
ble to that of the BAX/BAK deficient D3 cells, and the third cell
line also eventually formed tumors (Figure 4A). In contrast, all
three BMK cell lines heterozygous for BIM and two of the three
BMK cell lines wild-type for BIM were as nontumorigenic asCANCER CELL : MARCH 2005the W2 control cells, while a single BMK cell line that ex-
pressed BIM (BIM+/+A) displayed modest tumorigenic activity
(Figure 4A). Thus, BIM deficiency promotes epithelial tumori-
genesis nearly as well as loss of BAX and BAK (p < 0.05), al-
though unlike the E-myc B cell lymphomas (Egle et al., 2004),
we did not observe haploinsufficiency. As BAX and BAK are
absolutely required for apoptosis, their deficiency may be more
effective at blocking apoptosis than the loss-of-function of one
of the upstream BH3-only proteins such as BIM.
To address the possibility that BH3-only protein deficiency
may shift the balance toward the antiapoptotic state and that
deletion of any BH3-only protein would nonspecifically pro-
mote tumorigenesis, we tested the tumorigenic potential of
E1A plus p53DD-transformed puma−/− BMK cells (Figure 4B)
derived from PUMA-deficient mice (Villunger et al., 2003). The
observation that PUMA-deficient transformed BMK cells were231
A R T I C L EFigure 4. BIM suppresses tumorigenesis and con-
fers paclitaxel sensitivity in vivo
A: BIM deficiency facilitates tumor growth. Three
independent transformed BMK cell lines of each
genotype (bim+/+, bim+/−, or bim−/−) were in-
jected subcutaneously into nude mice, and tu-
mor growth was monitored over time. Each
point represents the average tumor volume for
five animals.
B: PUMA deficiency is not sufficient to promote
tumorigenesis. Two independent transformed
wild-type (PUMA+/+A and B) and PUMA-defi-
cient (PUMA−/−A and B) BMK cell lines were de-
rived from primary BMK cells from puma−/− and
puma+/+ mice, littermates from a puma+/− cross.
The E1A-alone transformed BMK cell line p53−/− A
similarly derived from p53−/− mice is shown as a
control. Tumor formation was performed as de-
scribed above.
C: PUMA-deficient cells are sensitive to pacli-
taxel but resistant to thapsigargin. PUMA+/+A
and B and PUMA−/−A and B were treated with
100 nM paclitaxel or 1 M thapsigargin, and via-
bility was evaluated by trypan blue exclusion af-
ter 72 hr or 24 hr of treatment, respectively, as
described above. Results are presented as rela-
tive survival with standard deviation.
D: BIM deficiency abrogates paclitaxel-medi-
ated inhibition of tumorigenesis. BIM+/+A and
BIM−/−A cells expressing RFP were injected sub-
cutaneously into nude mice. Three days after
implantation, treatment with paclitaxel at 16
mg/kg dissolved in normal saline or vehicle (84.3
mg/ml cremorphor and 8% [v/v] ethanol dis-
solved in normal saline) was given intraperitone-
ally for five consecutive days. Day 0 represents
the day before treatment. Mice were ear-
tagged and individual mice were monitored
over time using a whole-animal fluorescence
imaging system to monitor tumor growth. One
representative animal of each treatment group
is shown.
E: Quantitation of BIM-dependent paclitaxel
responsiveness. The response of BIM+/+A and
BIM−/− A implanted into nude mice to vehicle
or paclitaxel was quantitated and categorized.
Complete response is defined as the complete
disappearance of the RFP signal, partial re-
sponse is defined as progressive loss of RFP signal beyond three weeks following treatment, but still detectable, and no response is defined as no detectable
loss of RFP signal. The number of mice showing a response in each category is shown over the total number of mice in each group, and the percent
responding is shown in parenthesis.
F: BIM deficiency abrogates paclitaxel-mediated inhibition of tumor progression of established tumors. Six mice bearing subcutaneous tumors of either
BIM+/+A or BIM−/−A were divided into vehicle and paclitaxel groups, with three mice in each group. When the tumors reached 0.5 cm in diameter (day
0), treatment with paclitaxel at 16 mg/kg or vehicle was given intraperitoneally for five consecutive days (day 1–5), and the average tumor volume of
each group, with standard deviation, is shown as a function of time. Double arrow indicates the days of drug treatment.as nontumorigenic as the W2 control cells indicates that in
contrast to BIM deficiency, PUMA deficiency was not sufficient
to promote tumorigenesis of epithelial cells (Figure 4B). In addi-
tion, PUMA-deficient cells were sensitive to paclitaxel, but dis-
played resistance to thapsigargin, an inducer of ER-stress-
mediated apoptosis (Figure 4C), consistent with a previous
study (Reimertz et al., 2003). Thus, although BIM and PUMA
are both proapoptotic BH3-only BCL-2 antagonists, their func-
tions are apparently pathway-specific.
BIM confers paclitaxel sensitivity in vivo
We investigated the role of BIM in the apoptotic response to
paclitaxel in vivo, by testing the ability of the drug to prevent232tumorigenesis. To visualize injected cells noninvasively, trans-
formed BMK cell lines BIM+/+A and BIM−/−A were engineered
to express red fluorescent protein (RFP), and the mice were
monitored by whole-animal optical imaging. Figure 4D shows
representative mice from each treatment group (vehicle or
paclitaxel) prior to and after paclitaxel administration. BIM+/+A
cells persisted in the vehicle control-treated animals and
eventually formed tumors of 0.5 cm in diameter by eight
weeks, whereas the RFP signal progressively regressed and
completely disappeared after paclitaxel treatment, and no tu-
mors formed during the total 14 weeks of monitoring. In con-
trast, BIM−/−A cells persisted in both the paclitaxel and vehicle
control groups for over three weeks, and tumors formed withinCANCER CELL : MARCH 2005
A R T I C L Esix weeks, irrespective of paclitaxel treatment. Whereas only
one of five mice bearing BIM−/−A cells responded partially to
paclitaxel, 7 of 8 mice bearing BIM+/+ cells responded com-
pletely or partially (Figure 4E). Thus, BIM is required for pacli-
taxel responsiveness in vivo as well as in vitro.
To test the efficacy of paclitaxel on established tumors,
BIM+/+A and BIM−/−A cells were implanted subcutaneously into
nude mice, and paclitaxel or vehicle treatment was initiated
when tumors reached 0.5 cm in diameter. Subsequent monitor-
ing of tumor volume (Figure 4F) revealed that paclitaxel did not
affect the growth rate of BIM-deficient tumors (BIM−/−A) but
induced striking regression of tumors bearing BIM (BIM+/+A)
that persisted during the six weeks of observation. Thus, BIM
is a major determinant in the response of tumors to paclitaxel,
both during tumor development and in established tumors.
H-ras/MAPK signaling promotes BIM
degradation in proteasomes
It has been reported recently that phosphorylation of BIM by
the ERK1/2 pathway accelerates BIM-EL degradation in pro-
teasomes (Ley et al., 2004; Luciano et al., 2003). Therefore, we
explored whether RAS prevented BIM induction by paclitaxel
by inducing its phosphorylation and turnover. To obviate any
contribution of cell death to BIM turnover, the effect of H-ras
on BIM stability was assessed in the BAX/BAK-deficient D3
cells. D3.zeo-2 and D3.Hras-1 cells were incubated with or
without paclitaxel for 24 hr, the protein synthesis inhibitor
cycloheximide (CHX) was added, and the subsequent decay in
BIM levels was monitored by Western blotting. In the absence
of paclitaxel, BIM-EL levels fell slowly in D3.zeo-2 cells, with a
half-life in excess of four hours, but H-ras expression ac-
celerated BIM turnover to a half-life of less than two hours (Fig-
ure 5A). Though paclitaxel enhanced BIM stability in the D3.
zeo-2 cells, BIM turnover was greatly accelerated in the D3.
Hras-1 cells (Figure 5A). Thus, paclitaxel enhances BIM sta-
bility, but H-ras expression facilitates BIM turnover even in the
presence of paclitaxel.
To determine if the degradation of BIM-EL proceeded via a
proteasome-dependent pathway, we examined BIM stability in
the presence of the proteasome inhibitor epoxomicin. Signifi-
cantly, epoxomicin completely blocked BIM-EL degradation in
the absence (Figure 5B) or presence (Figure 5C) of paclitaxel
and restored BIM accumulation to H-ras expressing cells (Fig-
ures 5B and 5C). Moreover, in D3.zeo-2 cells, the slower mi-
grating forms of BIM-EL representing phosphorylated BIM-EL
accumulated over time following epoxomicin treatment, sug-
gesting that BIM-EL phosphorylation occurred prior to its deg-
radation in proteasomes (Figure 5B and 5C). Thus, the en-
hanced turnover of BIM in H-ras expressing cells could be
attributed to stimulation of BIM phosphorylation and degrada-
tion via the ubiquitin proteasome pathway. Since paclitaxel in-
duces BIM accumulation, and BIM function is required for
apoptosis induction by paclitaxel, this suggests that H-ras
expression suppresses BIM accumulation by targeting BIM for
degradation in proteasomes, thereby blocking apoptosis.
Since BIM protein levels reportedly can be regulated at the
transcription level through the MAPK, AKT/Forkhead, or JNK
pathways in certain cell types (Marani et al., 2004; Putcha et
al., 2003), we tested whether RAS also blocks BIM induction
in response to paclitaxel at the mRNA level. The basal BIM
mRNA levels in BMK cells with (D3.Hras-1) or without (D3.zeo-2)CANCER CELL : MARCH 2005Figure 5. H-ras promotes BIM degradation in proteasomes
A: Phosphorylation by H-ras promotes BIM turnover. D3.zeo-2 and D3.Hras-1
were untreated or treated with 300 nM paclitaxel for 24 hr and then
treated with 0.4 g/ml of CHX or 0.4 g/ml of CHX and paclitaxel, respec-
tively. Cell lysates were analyzed by Western blotting at the indicated times
for BIM. Actin is shown as a loading control.
B and C: Proteasome inhibition rescues BIM turnover. D3.zeo-2 and D3.Hras-1
cells were untreated (B) or treated with 300 nM paclitaxel (C) for 24 hr and
then 0.4 g/ml of CHX or the combination of CHX and 200 nM of epoxo-
micin was added to the cells. Cell lysates were analyzed by Western blot-
ting at the indicated times for BIM. α-tubulin is shown as a loading control.
D: BIM is transcriptionally upregulated in response to paclitaxel that is not
significantly affected by H-ras. Total RNA was prepared from D3.zeo-2 and
D3. Hras-1 cells following 300 nM paclitaxel treatment at the times indi-
cated, and level of BIM mRNA was analyzed by RT-PCR. Standard devia-
tion was calculated from the triplicate samples.H-ras expression were comparable (Figure 5D). After 48 hr of
paclitaxel treatment, the mRNA level increased modestly in
both D3.zeo-2 cells and D3.Hras-1 cells, suggesting that up-
regulation of BIM mRNA by paclitaxel may contribute to accu-
mulation of the protein independently of H-ras. We conclude
that the predominant mechanism by which H-ras prevents BIM
induction by paclitaxel is stimulation of BIM turnover.233
A R T I C L EProteasome inhibition restores BIM-dependent apoptosis
by paclitaxel in the presence of H-ras
If H-ras renders cells refractory to paclitaxel predominantly by
promoting BIM degradation, proteasome inhibitors might re-
store cell death in H-ras-expressing cells by blocking BIM turn-
over, and only BIM-expressing cells should be sensitized to
paclitaxel. To test this hypothesis, BIM+/+A, BIM+/+A.Hras-B,
and BIM−/−A.Hras-C were treated with paclitaxel, epoxomicin,
or both. At time points and drug concentrations where the BIM
wild-type cells were refractory to paclitaxel or epoxomicin
alone, the combined treatment was highly cytotoxic, even
when H-ras was expressed (Figure 6A). In striking contrast,
BIM-deficient cells expressing H-ras were markedly resistant
to the combination of paclitaxel and epoxomycin (Figure 6A).
The small epoxomycin and paclitaxel synergy observable at 24
hr in BIM-deficient cells might indicate the existence of protea-
some targets other than BIM. Restoration of paclitaxel sensitiv-
ity by epoxomicin in BIM+/+A.Hras-B cells correlated with res-
toration of BIM accumulation (Figure 6B). This is not a specific
effect of epoxomicin, because the proteasome inhibitor Vel-
cade, which is currently in clinical trials as an anticancer agent
and has been approved by the FDA for use in multiple my-
eloma, also restored BIM induction by paclitaxel and abrogated
H-ras-dependent resistance in BIM wild-type but not BIM-defi-
cient cells (Figures 6C and 6D). Thus, H-ras inhibits paclitaxel-
mediated apoptosis by phosphorylating BIM via the MAPK
pathway and promoting its degradation in proteasomes.
Proteasome inhibition abrogates H-ras-dependent
paclitaxel resistance in vivo
The ability of proteasome inhibitors to abrogate the paclitaxel
resistance conveyed by H-ras encouraged us to test whether
proteasome inhibition could sensitize H-ras-expressing cells
to paclitaxel in vivo. The efficacy of cotreatment with VelcadeFigure 6. Proteasome inhibition restores BIM
function to H-ras expressing cells
A: Epoxomicin abrogates H-ras-dependent re-
sistance to paclitaxel in BIM wild-type but not in
BIM-deficient cells in vitro. BIM+/+A, BIM+/+A.
Hras-B, and BIM−/−A.Hras-C were treated with
12.5 nM epoxomicin alone or 100 nM paclitaxel
alone, or both, for 12 and 24 hr. Viability was
evaluated by trypan blue exclusion. Results are
presented as relative survival with error bars rep-
resenting standard deviation.
B: Epoxomicin rescues BIM induction by pacli-
taxel in the presence of H-ras. Cell lysates from
24 hr treatment were then subjected to Western
blotting for BIM. Control lysates without treat-
ment (C), paclitaxel alone (TX), the combina-
tion of epoxomicin and paclitaxel (B), and
epoxomicin alone (EP) are indicated.
C: Velcade abrogates H-ras-dependent pacli-
taxel resistance in BIM wild-type but not in BIM-
deficient cells in vitro. BIM+/+A, BIM+/+A.Hras-B,
and BIM−/−A.Hras-C were treated with 7.5 nM
Velcade alone or 100 nM paclitaxel alone, or
both, for 24 hr. Viability was evaluated by trypan
blue exclusion. Results are presented as relative
survival with error bars representing standard
deviation.
D: Velcade rescues BIM induction by paclitaxel in the presence of H-ras. Cell lysates of the above were subjected to Western blotting for BIM. Control
lysates without treatment (C), paclitaxel alone (TX), the combination of Velcade and paclitaxel (B), and Velcade alone (VE) are indicated.234and paclitaxel was compared to that with each drug alone or
to the vehicle control in BIM+/+A.Hras-B and BIM−/−A.Hras-C
BMK cells implanted subcutaneously into nude mice. BIM+/+A.
Hras-B and BIM−/−A.Hras-C were both highly tumorigenic (Fig-
ures 7A and 7B). The tumors formed by BIM+/+A.Hras-B re-
sponded poorly to either Velcade or paclitaxel alone, but the
cotreatment significantly reduced tumor growth (p < 0.01) (Fig-
ure 7A). In contrast, tumors formed by BIM−/−A.Hras-C BMK
cells responded poorly to the combination treatment (Figure
7B), demonstrating that the synergy between Velcade and
paclitaxel requires BIM. Thus, proteasome inhibition abrogated
the paclitaxel resistance in vivo imposed by H-ras, by rescuing
BIM responsiveness to paclitaxel.
Discussion
Many anticancer agents induce apoptosis, and chemoresis-
tance can occur when tumors are unable to efficiently engage
apoptotic programs. Since apoptotic defects are selected for
during tumorigenesis, the process of tumor evolution may also
select for drug resistance. Indeed, BIM has proven to be a tu-
mor suppressor both in epithelial solid tumors (Figure 4A) and
lymphomas (Egle et al., 2004), and also is a major determinant
in paclitaxel sensitivity (Figures 4D–4F). Similarly, H-ras and the
MAPK pathway are commonly mutated in human tumors, and
we show that RAS/MAPK activation suppresses BIM accumu-
lation and thereby ablates the proapoptotic response to pacli-
taxel. Thus, common mutational events that arise during tumor
formation can directly or indirectly disable the apoptotic ma-
chinery and confound cancer treatment.
Just as BCL-2 is an oncoprotein, evidence is emerging that
several of the BH3-only proteins may suppress the develop-
ment of very specific types of tumors. Mice lacking BID have
an increased tendency to develop chronic myelomonocyticCANCER CELL : MARCH 2005
A R T I C L EFigure 7. Velcade-enhanced paclitaxel-induced
apoptosis in vivo requires BIM
A and B: BIM+/+A.Hras-B or BIM−/−A.Hras-C cells
were injected subcutaneously into nude mice.
When the tumors reached 0.5 cm in diameter
(day 0), the mice were assigned randomly into
each of the following groups with 5–9 mice/
group: control, Velcade, paclitaxel, or Velcade
and paclitaxel. Each mouse received 0.55 mg/
kg Velcade and/or 10 mg/kg paclitaxel intra-
peritoneally on days 1, 3, 5, 7 as arrows indicate.
Mannitol dissolved in normal saline was used as
vehicle for Velcade; 52.7 mg/ml cremophor
and 5% (v/v) ethanol dissolved in normal saline
was used as vehicle for paclitaxel. Day 0 repre-
sents the day before treatment. Each point rep-
resents the average tumor volume of each
group, with standard deviation. Note that Vel-
cade sensitized H-ras-expressing BMK cells to
paclitaxel in the presence of BIM (A) but failed
to sensitize H-ras-expressing BMK cells to pacli-
taxel in the absence of BIM (B).
C: A model for the mechanism by which H-ras
modulates BIM and confers resistance to pacli-
taxel. See text for details.leukemia (Zinkel et al., 2003), and some aged BAD-deficient
mice develop diffuse large cell lymphoma (Ranger et al., 2003).
Similarly, either PUMA knockdown or BIM deficiency promotes
the development of B cell lymphomas in E-myc transgenic
mice (Egle et al., 2004; Hemann et al., 2004). The contribution
of BH3-only proteins to suppression of epithelial solid tumor
formation, however, was unknown. We showed previously that
BAX- or BAK-dependent apoptosis suppresses tumorigenesis
of transformed BMK cells independently from p53 function
(Degenhardt et al., 2002a). As BH3-only proteins function up-
stream of BAX and BAK, identification of those BH3-only pro-
teins, and the apoptotic pathways that they regulate to control
apoptosis during solid tumor formation, is of great interest.
Here we demonstrate that BIM, but not PUMA, deficiency pro-
motes epithelial tumorigenesis (Figures 4A and 4B). The human
Bim gene (official name BCL2L11) may well also be a tumor
suppressor, because it is located in a region (chromosome
2q13) where alterations, predominantly deletions, have been
reported in human malignancies, more than half of the cases
being epithelial in origin (http://cgap.nci.nih.gov/Chromosomes/
Mitelman).
Since the BMK cells studied here had been transformed with
genes that disrupt the RB and p53 pathways, BIM clearly con-
trols a checkpoint independent of those major routes to tumori-
genesis. BIM deficiency was somewhat less efficient in tumor
promotion than combined deficiency in BAX and BAK. As BAX
and BAK seem to be required for apoptosis mediated by all
BH3-only proteins, whereas the latter are activated by specific
stimuli (Cory and Adams, 2002), this result may well indicate
that another BH3-only protein can also contribute to epithelial
tumorigenesis. Indeed, PUMA and not BIM is induced by isch-
emic conditions in the tumor microenvironment in vivo during
BAX- and BAK-mediated tumor regression (Nelson et al.,
2004), and PUMA may synergize with BIM to suppress tumori-CANCER CELL : MARCH 2005genesis. As PUMA deficiency alone was insufficient to promote
epithelial tumorigenesis, PUMA function may only be mani-
fested in the absence of BIM. Alternatively, PUMA may be a
tumor suppressor in other situations, as it mediates both p53-
dependent and -independent apoptosis, and NOXA or other
BH3-only proteins may function redundantly with PUMA.
BIM has been implicated in mediating paclitaxel-induced
apoptosis in vitro (Bouillet et al., 1999; Sunters et al., 2003),
and we demonstrate here that there is an essential role of BIM
in paclitaxel-induced apoptosis in vivo. Paclitaxel not only ef-
fectively inhibited epithelial tumor establishment, but also strik-
ingly induced regression of established tumors. However, this
chemotherapeutic effect required BIM, because it was com-
pletely abrogated by BIM deficiency. Moreover, H-ras expres-
sion conferred resistance to paclitaxel-induced apoptosis by
promoting BIM degradation in proteasomes, and BIM inhibition
promoted both epithelial tumor growth and drug resistance.
Pertinently, combined chemotherapy with paclitaxel and the
MER/ERK inhibitor U0126 was shown to enhance induction of
cell death in human tumors (MacKeigan et al., 2000; McDaid
and Horwitz, 2001), but the underlying mechanism is not
known.
Here, we correlate RAS-dependent paclitaxel resistance and
BIM regulation by the RAS/MAPK pathway (Figure 7C). In
transformed BMK epithelial cells, paclitaxel caused upregula-
tion of both BIM mRNA and protein, resulting in BIM accumula-
tion and apoptosis. Although BIM has been shown to be regu-
lated transcriptionally by RAS or its downstream effectors in
different scenarios, basal levels of BIM mRNA and its upregula-
tion by paclitaxel were not significantly affected by H-ras. How-
ever, activation of the RAS/MAPK pathway prevented BIM in-
duction by paclitaxel by stimulating BIM phosphorylation and
degradation via the ubiquitin proteasome pathway, thereby
producing resistance to paclitaxel (Figure 7C). As BCL-2 and235
A R T I C L EMCL-1 bind to and compromise BIM function, we tested
whether phosphorylation of BIM by H-ras would modulate its
binding to BCL-2 and/or MCL-1, but this was not the case
(data not shown). Thus, phosphorylation of BIM by H-ras likely
regulates BIM protein levels and not its function per se.
Our studies demonstrate that proteasome inhibitors restore
BIM induction and abrogate H-ras-dependent resistance to
paclitaxel. Velcade, the first proteasome inhibitor to reach clin-
ical trials, shows in vitro and in vivo activity as a single agent
against multiple myeloma, chronic lymphocytic leukemia, and
prostate, pancreatic, and renal cell cancer (Adams and Kauff-
man, 2004). Preclinical studies have shown that Velcade also
produced additive or synergistic antitumor activity in a mouse
Lewis lung cancer model, when combined with paclitaxel or a
few other cytotoxic agents (Teicher et al., 1999), but the un-
derlying mechanism of the cooperative effect is not known.
A notorious oncogenic pathway activated by proteasome
degradation is the NF-κB pathway (Ravi and Bedi, 2004). Pro-
teasome inhibitors can diminish the ubiquitin-mediated turn-
over of the NF-κB inhibitor IκB, thereby extinguishing NF-κB
survival signaling and other activities to promote tumor pro-
gression. NF-κB is constitutively activated in many tumor
types, and it can also be induced by chemotherapy, radiation,
and other cellular stresses. Inhibition NF-κB activation has
been proposed as a mechanism of Velcade action (Adams,
2003a), but NF-κB-independent activity of Velcade has also
been reported (An et al., 2004). Our results identify an alterna-
tive pathway responsive to Velcade that may be both drug- and
tumor genotype-specific. Velcade sensitized BIM wild-type but
not BIM-deficient BMK cells expressing H-ras to paclitaxel-
induced apoptosis both in vitro and in vivo, indicating that this
paclitaxel/Velcade synergy is BIM-dependent. Thus, combina-
tion therapy with paclitaxel and proteasome inhibitors may be
particularly useful in treating paclitaxel-resistant tumors with
mutations activating MAPK signaling. Interestingly, combina-
tion therapy with Velcade and the paclitaxel-related drug do-
cetaxel was not always effective against pancreatic cancer,
which frequently harbors Rasmutations (Nawrocki et al., 2004),
suggesting that the regulation of chemotherapeutic responses
by BIM and H-ras may be influenced by yet other factors.
The armamentarium of potential anticancer drugs is expanding;
however, single agents may not suffice to achieve complete re-
mission. Velcade is currently being evaluated in combination with
paclitaxel, docetaxel, and a few other chemotherapeutic drugs in
Phase I and II clinical trials. As it is not likely feasible to clini-
cally test every possible combination of agents, the predictive
value of knowing what drugs to use to treat specific cancer
genotypes based on their mechanism of interaction can maxi-
mize the potential for effective treatment. Ultimately, successful
therapy may rely upon relating tumor genotype to its capacity
to response to specific agents, singly and in combination.
Experimental procedures
Materials
The materials were obtained as follows: cycloheximide, cremophore, and
D-mannitol (Sigma, St. Louis, MO); U0126, etoposide, thapsigargin, and
epoxomicin (Calbiochem, La Jolla, CA); paclitaxel (Calbiochem and Bristol-
Myers Squibb Co., Princeton, NJ); and Velcade (Millennium Pharmaceuti-
cals, Inc., Cambridge, MA).236Generation of stable cell lines
The generation of E1A plus p53DD transformed BMK cell lines were de-
scribed previously (Degenhardt et al., 2002b). The BMK cell lines were
grown in Dulbecco’s modified Eagle media (Gibco/Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum at 38.5°C. Stable BMK cells
expressing human BCL-2, H-ras, RAF-CAAX, Myr-AKT, or the vector con-
trols were derived by electroporation with pcDNA3.1-hBCL-2 (Nelson et al.,
2004), pcDNA1.H-rasV12 (Lin et al., 1995), pcDNA3.RAF-CAAX (provided
by Dr. Peter Sabbatini, UCSF, San Francisco, CA), pcDNA3.Myr-AKT (Plas
et al., 2001), or vector (W2, pcDNA3.1; D3, pcDNA3.1zeo, Invitrogen, Carls-
bad, CA), followed by selection (W2, geneticin; D3, zeocin). For RFP expres-
sion, cells were transfected with pDsRed-C1 (Clontech, Palo Alto, CA) and
selected with geneticin, and the pool of transfected cells was used for sub-
cutaneous injection in nude mice. Tumor formation in nude mice by subcu-
taneous injection was performed essentially as described previously (De-
genhardt et al., 2002a). Briefly, 107 cells were injected in each of 5 or more
mice for each cell line (NCR nu/nu athymic nude mice, 5–6 weeks of age;
Taconic, Germantown, NY), and tumor growth was monitored over time.
Western blotting
The following antibodies were used: rabbit anti-BIM (Axxora, LLC, San
Diego, CA); rabbit anti-mouse BMF (Abcam, Cambridgeshire, UK); rabbit
anti-PUMA (Nelson et al., 2004); goat anti-mouse BID and tBID (R&D Sys-
tems, Minneapolis, MN); rabbit anti-BAX, and anti-BAK (Upstate Biotech-
nology, Lake Placid, NY); mouse anti-p53 (Ab-1), mouse anti-E1A, mouse
anti-pan-ras, mouse anti-actin, and anti-α-tubulin (Oncogene, Cambridge,
MA); and rabbit anti-MAPK p42/p44 and phosphorylated MAPK p42/p44
(Cell Signaling Technology, Beverly, MA). Cell extracts were generated in
Laemmli buffer, and Western blotting was performed as previously de-
scribed (Nelson et al., 2004).
Phosphatase digestion of BIM
D3.zeo-2 and D3.Hras-1 cells were harvested in 2% CHAPS lysis buffer
with protease inhibitors, as previously described (Cuconati et al., 2003).
Whole cell lysates were incubated with lambda protein phosphatase (NEB,
Beverly, MA) at 30°C for two hours and then analyzed by Western blotting.
Real-time PCR
RT-PCR was carried out as previously described (Cuconati et al., 2003).
Gene-specific primer pairs and probe sequences for bim: forward (5#-TGC
GCC CGG AGA TAC G-3#), reverse (5#-CCT CCT TGT GTA AGT TTC GTT
GAA C-3#), and probe (5#- /56-FAM/CGA TCC GCC GCA GCT CCT GT/36-
TAMTph/-3#). Primers and probe for mouse gapdh PCR were obtained from
Applied Biosystems, which served as an internal control and were used to
normalize for variances in input cDNA.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/3/227/DC1/.
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